HK Market Bulletin Highlights: SEER TECH and Maike Pharma Initiate IPOs, Insilico Medicine Added to CSI Index Series

Stock News
06/15

Key corporate developments in the Hong Kong market are in focus today.

SEER TECH (06106) has commenced its public offering today, aiming to raise approximately HK$10 billion to further invest in robotics research and development. Eight cornerstone investors, including HHLRA and GF Fund, have participated.

Maike Pharma-B (02335) has also started its share offering today, targeting over HK$10 billion in funds. Cornerstone investors include Qiyuan Hong Kong and Everest Medicines (01952).

Insilico Medicine (03696) has been included in the China Securities Index series.

Ray Alliance Asset Management (01835) plans to acquire partnership interests in two intelligent driving-themed funds for a total of RMB 40 million.

Delip Holdings (01921) has secured a 10,000-ton order for oil well pipes from Egypt's General Petroleum Company.

SBP GROUP (01177) intends to use up to HK$20 billion for share buybacks and purchasing shares for incentive schemes.

Chenming Paper (01812) plans to sell a 90.05% equity and creditor interest in Royal View Hotel for approximately RMB 317 million.

OCT (Asia) (03366) announced that its subsidiary intends to publicly list for sale its 100% equity interest in OCT (Huizhou).

Mabwell-B (02493) disclosed that its clinical trial application for the injectable 6MW5311 has received FDA approval.

Vanke (02202) has obtained a loan facility of up to RMB 1.14 billion from Shenzhen Metro Group.

Nine Dragons Paper (02689) has secured a RMB 2 billion loan from several banks and has launched a tender offer to repurchase $400 million in perpetual capital securities to optimize its capital structure.

Financial Performance Updates

China Resources Land (01109) reported cumulative contracted sales of approximately RMB 93.51 billion for the first five months, representing a year-on-year increase of 7.7%.

Shimao Group (00813) announced cumulative contracted sales of about RMB 6.951 billion for the first five months.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10